RxDoctor Payments Data

Ashley Foster

Nurse Practitioner · Kokomo, INNPI 1144745563

Payments from drug & device makers

$780in general payments, 2019–2025

Across 10 payments — averaging $78.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$139
  • Otsuka America Pharmaceutical, Inc.$137
  • E.r. Squibb & Sons, L.L.C.$115
  • Teva Pharmaceuticals USA, Inc.$106
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$96
  • Alkermes, Inc.$90
  • plus $98 from 2 others

What the payments were for

  • Food & beverage$76798%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$780 in reported general payments places this provider in the 70th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$7,466
Medicare patients
23
Services billed
93

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole26$73,895
LybalviOlanzapine/Samidorphan Malate19$31,159
VraylarCariprazine Hcl16$24,729
TrintellixVortioxetine Hydrobromide19$9,721
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl31$9,393
Lurasidone Hcl25$5,730
Doxepin Hcl23$4,003
Aripiprazole33$3,557
Bupropion XlBupropion Hcl70$2,960
Vilazodone Hcl16$1,281
Buspirone Hcl84$1,198
Quetiapine Fumarate ErQuetiapine Fumarate32$1,182
Trazodone Hcl41$986
Hydroxyzine Hcl44$912
Gabapentin38$870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$137$73,89526 claims
Alkermes, Inc.Lybalvi$90$31,15919 claims
AbbVieVraylar$139$24,72916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Kokomo

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →